Is Bio-Techne Corporation (TECH) a Buy, Sell, or Hold?
Bio-Techne Corporation
NASDAQ:TECH
$71.465 USD
$0.23 (0.33%)
- Volume
- 1.21M
- Average Volume
- 4.7M
- Market Capitalization
- $11.19B
- P/E Ratio
- 100.65
- Dividend Yield
- 0.45%
- Price Target
- $73.00
- Year High
- $72.16
- Year Low
- $43.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.45
- Current Ratio
- $4.49
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kim Kelderman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TECH |
| CUSIP | 09073M104 |
| CIK | 0000842023 |
| Web | https://www.bio-techne.com |
| Phone | 612 379 8854 |
| Currency | USD |
| Employees | 3100 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.14 |
| Payout Ratio | 0.45 |
| Current Ratio | 4.49 |
| Quick Ratio | 3.18 |
| Cash Ratio | 1.37 |
Sales & Book Value
| Annual Sales | $1.22B |
| Price / Sales | 9.24 |
| Cash Flow | 1.73 |
| Price / Cash Flow | 41.50 |
| Price / Book | 5.34 |
Price Target and Rating
| Average Stock Price Forecast | $73.00 |
| High Stock Price Forecast | $79.00 |
| Low Stock Price Forecast | $50.00 |
| Forecast Upside/Downside | -2.10% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 26 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.46 |
| Trailing P/E Ratio | 100.65 |
| PEG Ratio | -6.96 |
| P/E Growth | -6.96 |
| Net Income | $73.4M |
| Net Margin | 9.05% |
| Pretax Margin | 12.15% |
| Return on Equity | 5.49% |
| Return on Assets | 4.30% |
Financials Score
| AltmanZ Score | 15.94 |
| Piotroski Score | 8.00 |
| Working Capital | 534.77M |
| Total Assets | 2.55B |
| Ebit | 157.65M |
| Market Cap | 11.15B |
| Total Liabilities | 465.3M |
Poll Results
About Bio-Techne Corporation (NASDAQ:TECH) Stock
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifyi ... ng proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
2026-07-08 06:30:00
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing MINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.
2026-07-06 12:17:00
BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-07-02 05:31:48
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
2026-07-02 05:31:00
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.
2026-06-30 13:13:00
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-06-29 16:21:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
2026-06-29 14:00:00
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 29, 2026
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
2026-06-29 13:59:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Frequently Asked Questions
-
What is the current Bio-Techne Corporation (TECH) stock price?
-
Bio-Techne Corporation(NASDAQ:TECH) stock price is $71.465 in the last trading session. During the trading session, TECH stock reached the peak price of $72.16 while $43.2 was the lowest point it dropped to. The percentage change in TECH stock occurred in the recent session was 0.33% while the dollar amount for the price change in TECH stock was $0.23.
-
TECH's industry and sector of operation?
-
The NASDAQ listed TECH is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TECH?
-
David Clair | Vice President of Investor Relations
James T. Hippel | Executive Vice President of Finance & Chief Financial Officer
Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer
Steve Crouse | President of Diagnostics & Spatial Biology Segment
Kim Kelderman | Chief Executive Officer, President & Director -
How many employees does TECH have?
-
Number of TECH employees currently stands at 3100. TECH operates from 614 McKinley Place N.E., Minneapolis, MN 55413, US.
-
Link for TECH official website?
-
Official Website of TECH is: https://www.bio-techne.com
-
How do I contact TECH?
-
TECH could be contacted at phone #612 379 8854 and can also be accessed through its website. TECH operates from 614 McKinley Place N.E., Minneapolis, MN 55413, US.
-
How many shares of TECH are traded daily?
-
The average number of TECH shares traded daily for last 3 months was 4.7M.
-
What is the market cap of TECH currently?
-
The market value of TECH currently stands at $11.19B with its latest stock price at $71.465